Therapy
Omalizumab
Humanised IgG1κ anti-IgE mAb: binds free IgE (same epitope as FcεRI binding site on IgE) → prevents IgE loading onto mast cells/basophils → FcεRI receptor downregulates (requires IgE ligand for surface expression) → less mast cell arming → reduced degranulation response to allergens.
Also called: Xolair, anti-IgE
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 2 and is affected by 0 concepts — mostly 1 molecule, 1 disease.
- 3Where it sits: therapy on the 15-step immune chain.
What it does
Approved: severe allergic asthma, CSU (urticaria ASTERIA I+II: CR 36% vs 8%), food allergy (OUtMATCH 2024: 67% tolerated peanut challenge - FDA 2024).
Its connections at a glance
Each dot is a concept directly linked to Omalizumab. Colours show the kind of concept.
Learn next
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I021 · concept status: established. Select any connection above to inspect evidence for that specific link.